share_log

Needham Reiterates Buy on Vir Biotechnology, Maintains $19 Price Target

Benzinga ·  Nov 1 18:09  · Ratings

Needham analyst Joseph Stringer reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $19 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment